Background/Aims
The purpose of this study was to develop a neural network (NN) pharmacodynamic (PD) model that correlates the inhibition of ex vivo platelet aggregation by orbofiban, an oral GPIIb/IIIa antagonist, with the administered dose and patient characteristics.
Methods
Data were obtained from a Phase‐II dose‐finding study in patients presenting with acute coronary syndromes. A back‐propagation NN was designed to predict drug effect measured at pre‐dose and 4 and 6 hours on treatment days 1, 28, and 84 (9 responses/patient). The training set (TS) consisted of patients for whom complete response profiles were reported (n=67), and remaining patients were included in the validation data set (VS; n=47). The concentration‐effect relationship was described also using a population inhibitory sigmoidal model, and a comparison of the predictive performances of both models was performed.
Results
The final NN reasonably described orbofiban PD from sparse data sets (r2=0.83 & 0.61; TS & VS) without specifying a structural model or drug concentrations. Despite considerable inter‐patient variability in response‐time profiles, the population model revealed a strong correlation between drug concentration and effect and exhibited greater precision than the NN model.
Conclusions
Although the population model showed greater precision, these results suggest that NNs may be useful for predicting drug PD when plasma concentrations are relatively unpredictable or unavailable.
Clinical Pharmacology & Therapeutics (2005) 77, P92–P92; doi:
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.